New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Recruiting
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2025
Locations: Laurelton Heart Specialist P.C., Rosedale, New York
Conditions: Chronic Heart Failure
IVIG for Infection Prevention After CAR-T-Cell Therapy
Recruiting
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Hematologic Malignancies
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Principal Investigator, New York, New York
Conditions: Persistent Corneal Epithelial Defect
Vancomycin Study in Multiple Sclerosis (MS)
Recruiting
The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/18/2025
Locations: Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York, New York
Conditions: Multiple Sclerosis
TVMR With the Innovalve System Trial - Early Feasibility Study
Recruiting
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Cornell, New York, New York
Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
Recruiting
This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York
Conditions: Lung Cancer
Nephrotic Syndrome Study Network
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Vaping and Smoking Project in People With Schizophrenia
Recruiting
The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence and contributing to the development of vaping cessation interventions amongst people with schizophrenia, the leading preventable cause of death in the US.
Gender:
ALL
Ages:
Between 21 years and 50 years
Trial Updated:
04/17/2025
Locations: University at Buffalo, Buffalo, New York
Conditions: Acute Abstinence From Cigarettes vs E-cigarettes (ENDS)
The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.
Recruiting
The goal of this study is to determine whether erectile function is differentially impacted by a single plant-based meat meal versus a single animal meat meal in healthy men with normal erectile function.
Gender:
MALE
Ages:
Between 18 years and 32 years
Trial Updated:
04/17/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Erectile Dysfunction
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Recruiting
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York
Conditions: Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
A Study of Avutometinib for People With Solid Tumor Cancers
Recruiting
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.
Gender:
ALL
Ages:
Between 3 years and 30 years
Trial Updated:
04/17/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Recruiting
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Memorial Sloan Kettering Suffolk-Commack, Commack, New York
Conditions: Adrenocortical Carcinoma, ACC, Metastatic Adrenocortical Carcinoma